Stocksigma LogoStocksigma Logo

Caplin Point Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)

■ Revenue: 630 (+17.9% YoY | +3.2% QoQ) ■ EBITDA: 223 (+18.0% YoY | +4.6% QoQ) ■ EBITDA Margin (%): 35.4 (+2 bps YoY | +46 bps QoQ) ■ PAT: 178 (+15.3% YoY

Caplin Point Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore)

Caplin Point Laboratories Ltd · Outcome · 12 Nov 2026, 6:38 pm

Caplin Point Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) ■ Revenue: 630 (+17.9% YoY | +3.2% QoQ) ■ EBITDA: 223 (+18.0% YoY | +4.6% QoQ) ■ EBITDA Margin (%): 35.4 (+2 bps YoY | +46 bps QoQ) ■ PAT: 178 (+15.3% YoY | +0.7% QoQ) ■ EPS (INR): 23.4 (+15.4% YoY | +0.7% QoQ) Caplin Point Laboratories Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crore) Segmental Performance Rest of the World ■ Revenue: 500 (+17.1% YoY | +5.1% QoQ) ■ EBIT: 183 (+17.4% YoY | +15.7% QoQ) ■ EBIT Margin (%): 36.6 (+8 bps YoY | +336 bps QoQ) USA ■ Revenue: 130 (+21.3% YoY | -3.4% QoQ) ■ EBIT: 16.3 (+12.3% YoY | -50.9% QoQ) ■ EBIT Margin (%): 12.6 (-100 bps YoY | -1219 bps QoQ)

Original exchange filing (PDF)

More announcements from Caplin Point Laboratories Ltd

All Caplin Point Laboratories Ltd announcements